The opportunities that I have described above are unprecedented in modern medicine. We have an amazing arsenal at our disposal. Few people have the desire or will to take on challenges so enormous they could fundamentally change the world for the better, and fewer still have the opportunity to actually do it. Advanced Cell Technology – our team and you, our shareholders, have that opportunity. We did not spend all this time; fix all these problems; bring on this board of directors and create all of these solutions to fail. We are so close to helping solve some of the biggest unmet medical needs in the world. But this amount of opportunity cannot be addressed overnight. If our stakeholders are patient and support our efforts, the catalysts for our success are within our grasp.
Oh I see, so once again the success of ACTC lies with the stakeholders 'patience and support"? Wow, if that were true this company would be in the Fortune 500 because many of us have stood strong despite dismal pps and a tongue lashing from Rabin just a few weeks ago. He needs to get off the blame game and give a "THANK YOU SHAREHOLDERS" for our loyalty. Hey Gary, get out of that financial cut throat faceless wizardry you learned in college and take a humanization course, where investors are seen as people and not figures on a lap-top. Hey Gary, I've got a catalyst for ya'......
The success of ACT lies with the science and management, not the shareholders. We're just along for the ride.
Somewhere in his latest presentation he reminded everyone that the company can't screw this up. When your the lead company, in an emerging biotech industry, cloaked in what some consider to be an ethical and moral debate, you have an obligation to make sure that you get it right. So like it or not patience is our only option. The FDA is not going to let the industry go any faster then they are comfortable.
His statement about the shareholders was bush league. I also doubt that shareholders concerned about the RS had a significant impact on the share price. Dilution and the warrant holders selling was likely a greater impact. But overall I'm going to give the guy credit for getting the company through a very tough period - well, almost through.
Sentiment: Strong Buy
Well, Keep, you can view it through that prism of immediate gratification (personally, I'm up 25% from where I bought back in), but I'm looking it as a declaration that there is some closure to some of the past overhangs along with advancements in the lab/trials being made. Gary speaking or blogging had nothing to do with the pullback. Millions of shares were sold ahead of the news and you know, as well as I, that in biotech, the traders always sell the news. Now, investors will buy when the opportunity presents itself. Guess we just have a different world view ... who knew?
So when someone asks "should Ibuy here, or wait for the price to go down to $.06"? I'd ask where do you see this company 5 and 10 years from now? What do you think the price will be? And, read the conclusion above and ask yourself if a $.02 difference in acquisition price really matters.
I understand the math. My point is about the people sitting on the fence stressing over $.02 will wake up and the price will be 20, 50 or 100% above where it is today and then what?
If they like the stock for the future, buy some here, if it dips buy some more, but sitting around discussing a few pennies now doesn't make sense. Your chance of getting in at the absolute bottom is pretty slim.
Yes, a $0.02 difference in the buy price matters a lot. If I decide to invest $10,000 in actc, can get 166,666 shares @ 0.06 or 125,000 @ 0.08. Then, 10 years from now when the price will be, say, $10, in those two scenarios I would have respectively an investment of $1,666,666 or $1,250,000. It's a $416,666 difference just for $0.02 when I bought.